ALK and non-small cell lung carcinoma: The mechanisms behind ALK rearrangement and increased thrombotic risk in NSCLC are unclear but some studies in lymphomas with ALK mutations suggest the ALK rearrangement results in increased STAT3 signaling and inflammation [77].